SCHEMBL717145

SCHEMBL717145

Cc1cc(Oc2ccc(NC(N)=O)cc2)c[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.51
ALDH1A1 P00352 5/20 0.50
GLA P06280 1/20 0.50
KIF11 P52732 1/20 0.46
HPGD P15428 4/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX12 P18054 1/20 0.45
CYP2C19 P33261 1/20 0.45
PEPD P12955 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 2/20 0.42
CRHBP P24387 1/20 0.42
RAB9A P51151 1/20 0.42
CRHR2 Q13324 1/20 0.42
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
LTA4H P09960 1/20 0.42
CDK8 P49336 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073790 0.82 CA12 (0.54) HPGDSMN1; SMN2NPC1CRHBPRAB9A
SCHEMBL13750226 0.80 KIF11 (0.70) HSD17B10ALDH1A1GLAKIF11HPGD
SCHEMBL7823002 0.75 PEPD (0.77) HSD17B10ALDH1A1GLAHPGDCYP3A4
SCHEMBL5528916 0.75 SMN1; SMN2 (0.66) HSD17B10ALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL4092732 0.74 NPC1 (0.78) HSD17B10ALDH1A1GLAHPGDCYP3A4
SCHEMBL282051 0.73 CDK8 (0.65) CDK8
SCHEMBL282329 0.73 ALDH1A1 (0.59) ALDH1A1HPGDCYP3A4SMN1; SMN2NPC1
SCHEMBL4092538 0.73 CDK8 (0.58) ALDH1A1KIF11HPGDSMN1; SMN2NPC1
SCHEMBL282086 0.73 RAF1 (0.60) SMN1; SMN2NPC1RAB9ACDK8
SCHEMBL5008975 0.72 HSD17B10 (0.58) HSD17B10ALDH1A1GLAHPGDCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 HSD17B10 1021/4885ALDH1A1 112/4885GLA 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.